Related Experiment Video
Updated: Aug 16, 2025
Rodent Model of Intestinal Ischemia-Reperfusion Injury via Occlusion of the Superior Mesenteric Artery
Published on: October 20, 2023
Intraluminal oxygen mitigates acute mesenteric ischaemia: a systematic review of methods and outcomes in animal
Daniel Joh1,2, Mathew Morreau1,3, Angela Lee1,2
1Surgical and Translational Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Background:
Acute Mesenteric Ischaemic (AMI) is a rare condition with significant morbidity and mortality. Many causes of AMI exist, which usually begin with mucosal injury. Onset is insiduous and there is frequent diagnostic delay. Current treatments can only control established injury and prevent propagation, hence new interventions are needed. The prevention and treatment of AMI by intraluminal delivery of oxygen has yet to be investigated in the clinical setting. This article aims to systemically review experimental studies investigating this novel therapy.
Methods:
Following the PRISMA guidelines, searches of PubMed and Ovid MEDLINE databases were performed up to June 2022. Two independent investigators extracted the data.
Results:
There were 20 experimental studies, 16 of which used an occlusive ischaemia reperfusion model. Six different formulations were used to deliver intraluminal oxygen, with perflurocarbon being the most common. Studies consistently showed local and systemic benefits. Intraluminal oxygen therapy improved histological severity of mucosal injury in all studies when oxygen was delivered during the ischaemia phase, but could cause harm if given during the reperfusion phase. Improvement was also demonstrated in endpoints assessing intestinal function, biomarkers of intestinal damage, measures of systemic physiological derangement and mortality.
Conclusion:
Intraluminal oxygenation appears to be an effective treatment for AMI. There remain significant questions regarding optimal timing and delivery formulation before clinical translation of this treatment strategy.
Insights
Intraluminal oxygen therapy shows promise for treating acute mesenteric ischemia (AMI). Delivering oxygen during ischemia improved outcomes, but harm occurred during reperfusion, requiring further research on optimal timing and formulation.
Area of Science:
- Gastroenterology
- Surgical Innovation
- Experimental Therapeutics
Background:
- Acute Mesenteric Ischemia (AMI) is a rare but serious condition with high mortality and diagnostic challenges.
- Current treatments for AMI focus on managing established injury, highlighting the need for novel therapeutic strategies.
- Intraluminal oxygen delivery represents an unexplored approach for preventing and treating AMI.
Approach:
- A systematic review of experimental studies investigating intraluminal oxygen therapy for AMI was conducted.
- PRISMA guidelines were followed for database searches (PubMed, Ovid MEDLINE) up to June 2022.
- Data extraction was performed independently by two investigators.
Key Points:
- Twenty experimental studies were reviewed, with 16 utilizing an occlusive ischemia reperfusion model.
- Perfluorocarbon was the most common formulation for intraluminal oxygen delivery.
- Therapy demonstrated consistent local and systemic benefits, improving mucosal injury, intestinal function, and reducing mortality when administered during ischemia.
Conclusions:
- Intraluminal oxygenation presents a potentially effective treatment for AMI.
- Further investigation is crucial to determine optimal timing and delivery formulations for clinical application.
- Careful consideration of the reperfusion phase is necessary, as oxygen delivery during this period may be detrimental.
